Remove Biosimilars Remove Drug Development Remove Pharmaceutical Companies
article thumbnail

Leadership evolution in India’s pharmaceutical sector in 2025- Driving global growth and innovation

Express Pharma

Continued strategic focus on North America: US market accounts for anywhere between 30 per cent to 60 per cent of annual revenues for Leading Pharmaceutical companies in India. Companies will continue to acquire leadership capabilities with focus on these markets.

article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

In India, pharmaceutical companies responded to global environmental concerns and government mandates by adopting greener manufacturing techniques. First, advanced research and development (R&D) and biologics will be critical. This transition will require substantial investments in several key areas. and Europe.

article thumbnail

AI and automation to drive “substantial progress” in pharmaceutical analytical testing

European Pharmaceutical Review

The pharmaceutical analytical testing market is seeing significant growth following a greater incidence in the complexity of medicine development and higher demand for biologics and biosimilars, according to a report by Straits Research Pvt. Their analysis projected that the market will exceed a value of $15.46 billion by 2032.

article thumbnail

Amgen opens its most advanced manufacturing facility to date

European Pharmaceutical Review

Amgen drug development highlights – November 2023 In November 2023, Phase II trial results for immunotherapy tarlatamab demonstrated an ability to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer trial patients.

article thumbnail

Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Pharmaceutical Technology

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

article thumbnail

Digitalisation to boost quality management systems market

European Pharmaceutical Review

FDA publishes paper on AI/ML in drug development In 2022, North America had the largest revenue share in the global pharmaceutical quality management systems market, according to the report. These solutions eliminate the need for on-premise servers and hardware, reducing IT infrastructure costs for pharmaceutical companies.